Birdwatch Note
2024-09-20 16:25:20 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
レプリコンワクチンのベトナム治験では、プラセボ群にもワクチンを接種する(クロスオーバー)前の、治験期間３か月間中に死因を問わず約八千人中5人のワクチン群が死亡し(うちコロナ死1)、プラセボ群は約八千人中16人が死亡(うちコロナ死9)」という結果です。 下記pdfの28P目,資料の24P目 https://web.archive.org/web/20240120232711/https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_2.pdf#page=28 参加者の17.4%は両群とも60歳以上で↓ https://www.nature.com/articles/s41467-024-47905-1/tables/1 治験場となったベトナムでは年間1000人中7人程(3か月で八千人中14人程)が自然に死亡するので↓ https://data.worldbank.org/indicator/SP.DYN.CDRT.IN?locations=VN 投稿者のいうような危険性は示唆すらされておらず、５人のどの死亡も接種と関連があるとされていません。
Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1837044858072310006
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1837166163022991515
- noteId - 1837166163022991515
- participantId -
- noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
- createdAtMillis - 1726849520818
- tweetId - 1837044858072310006
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- レプリコンワクチンのベトナム治験では、プラセボ群にもワクチンを接種する(クロスオーバー)前の、治験期間３か月間中に死因を問わず約八千人中5人のワクチン群が死亡し(うちコロナ死1)、プラセボ群は約八千人中16人が死亡(うちコロナ死9)」という結果です。 下記pdfの28P目,資料の24P目 https://web.archive.org/web/20240120232711/https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_2.pdf#page=28 参加者の17.4%は両群とも60歳以上で↓ https://www.nature.com/articles/s41467-024-47905-1/tables/1 治験場となったベトナムでは年間1000人中7人程(3か月で八千人中14人程)が自然に死亡するので↓ https://data.worldbank.org/indicator/SP.DYN.CDRT.IN?locations=VN 投稿者のいうような危険性は示唆すらされておらず、５人のどの死亡も接種と関連があるとされていません。
Note Ratings
| rated at | rated by | |
| 2024-09-23 00:28:57 -0500 | Rating Details | |
| 2024-09-22 18:55:15 -0500 | Rating Details | |
| 2024-09-22 14:11:21 -0500 | Rating Details | |
| 2024-09-22 02:42:57 -0500 | Rating Details | |
| 2024-09-21 21:18:50 -0500 | Rating Details | |
| 2024-09-21 20:38:22 -0500 | Rating Details | |
| 2024-09-21 20:01:27 -0500 | Rating Details | |
| 2024-09-21 06:59:27 -0500 | Rating Details | |
| 2024-09-21 06:56:33 -0500 | Rating Details | |
| 2024-09-21 06:32:05 -0500 | Rating Details | |
| 2024-09-21 06:15:04 -0500 | Rating Details | |
| 2024-09-21 05:31:53 -0500 | Rating Details | |
| 2024-09-21 01:04:39 -0500 | Rating Details | |
| 2024-09-21 00:28:52 -0500 | Rating Details | |
| 2024-09-20 22:22:10 -0500 | Rating Details | |
| 2024-09-20 22:21:16 -0500 | Rating Details | |
| 2024-09-20 21:56:23 -0500 | Rating Details | |
| 2024-09-20 21:45:36 -0500 | Rating Details | |
| 2024-09-20 21:40:37 -0500 | Rating Details | |
| 2024-09-20 21:40:21 -0500 | Rating Details | |
| 2024-09-20 21:32:06 -0500 | Rating Details | |
| 2024-09-20 21:23:30 -0500 | Rating Details | |
| 2024-09-20 21:11:27 -0500 | Rating Details | |
| 2024-09-20 21:09:39 -0500 | Rating Details | |
| 2024-09-20 21:05:40 -0500 | Rating Details | |
| 2024-09-20 20:59:34 -0500 | Rating Details | |
| 2024-09-20 20:26:43 -0500 | Rating Details | |
| 2024-09-20 20:11:42 -0500 | Rating Details | |
| 2024-09-20 19:24:19 -0500 | Rating Details | |
| 2024-09-20 19:21:53 -0500 | Rating Details | |
| 2024-09-20 19:20:03 -0500 | Rating Details | |
| 2024-09-20 19:16:07 -0500 | Rating Details | |
| 2024-09-20 19:12:38 -0500 | Rating Details | |
| 2024-09-20 19:04:14 -0500 | Rating Details | |
| 2024-09-20 18:50:07 -0500 | Rating Details | |
| 2024-09-20 18:45:14 -0500 | Rating Details | |
| 2024-09-20 18:42:17 -0500 | Rating Details | |
| 2024-09-20 18:40:52 -0500 | Rating Details | |
| 2024-09-20 18:21:52 -0500 | Rating Details | |
| 2024-09-20 18:14:50 -0500 | Rating Details | |
| 2024-09-20 18:07:26 -0500 | Rating Details | |
| 2024-09-20 18:01:24 -0500 | Rating Details | |
| 2024-09-20 17:56:21 -0500 | Rating Details | |
| 2024-09-20 17:55:05 -0500 | Rating Details | |
| 2024-09-20 17:48:47 -0500 | Rating Details | |
| 2024-09-20 17:47:46 -0500 | Rating Details | |
| 2024-09-20 17:45:56 -0500 | Rating Details | |
| 2024-09-20 17:40:41 -0500 | Rating Details | |
| 2024-09-20 17:38:17 -0500 | Rating Details | |
| 2024-09-20 17:30:50 -0500 | Rating Details | |
| 2024-09-20 17:23:44 -0500 | Rating Details | |
| 2024-09-20 17:20:26 -0500 | Rating Details | |
| 2024-09-20 17:06:53 -0500 | Rating Details | |
| 2024-09-20 16:55:53 -0500 | Rating Details | |
| 2024-09-20 16:44:00 -0500 | Rating Details | |
| 2024-09-20 16:43:07 -0500 | Rating Details | |
| 2024-09-20 16:37:57 -0500 | Rating Details | |
| 2024-09-20 16:33:53 -0500 | Rating Details | |
| 2024-09-20 16:31:39 -0500 | Rating Details | |
| 2024-09-20 16:30:51 -0500 | Rating Details | |
| 2024-09-20 16:29:48 -0500 | Rating Details | |
| 2024-09-20 16:22:29 -0500 | Rating Details | |
| 2024-09-20 16:16:50 -0500 | Rating Details | |
| 2024-09-20 15:37:57 -0500 | Rating Details | |
| 2024-09-20 15:04:47 -0500 | Rating Details | |
| 2024-09-20 14:51:14 -0500 | Rating Details | |
| 2024-09-20 14:43:12 -0500 | Rating Details | |
| 2024-09-20 14:36:12 -0500 | Rating Details | |
| 2024-09-20 14:24:42 -0500 | Rating Details | |
| 2024-09-20 14:22:59 -0500 | Rating Details | |
| 2024-09-20 14:21:14 -0500 | Rating Details | |
| 2024-09-20 14:03:07 -0500 | Rating Details | |
| 2024-09-20 13:45:30 -0500 | Rating Details | |
| 2024-09-20 13:44:02 -0500 | Rating Details | |
| 2024-09-20 13:31:22 -0500 | Rating Details | |
| 2024-09-20 13:23:44 -0500 | Rating Details | |
| 2024-09-20 13:21:31 -0500 | Rating Details | |
| 2024-09-20 13:16:26 -0500 | Rating Details | |
| 2024-09-20 13:04:31 -0500 | Rating Details | |
| 2024-09-20 12:55:33 -0500 | Rating Details | |
| 2024-09-20 12:52:32 -0500 | Rating Details | |
| 2024-09-20 12:48:58 -0500 | Rating Details | |
| 2024-09-20 12:44:14 -0500 | Rating Details | |
| 2024-09-20 12:33:52 -0500 | Rating Details | |
| 2024-09-20 12:31:54 -0500 | Rating Details | |
| 2024-09-20 12:25:13 -0500 | Rating Details | |
| 2024-09-20 12:17:25 -0500 | Rating Details | |
| 2024-09-20 12:17:20 -0500 | Rating Details | |
| 2024-09-20 12:11:21 -0500 | Rating Details | |
| 2024-09-20 12:03:12 -0500 | Rating Details | |
| 2024-09-20 11:59:07 -0500 | Rating Details | |
| 2024-09-20 11:58:21 -0500 | Rating Details | |
| 2024-09-20 11:57:28 -0500 | Rating Details | |
| 2024-09-20 11:56:47 -0500 | Rating Details | |
| 2024-09-20 11:55:56 -0500 | Rating Details | |
| 2024-09-20 11:53:53 -0500 | Rating Details | |
| 2024-09-20 11:52:34 -0500 | Rating Details | |
| 2024-09-20 11:33:26 -0500 | Rating Details | |
| 2024-10-02 21:25:02 -0500 | Rating Details |